Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1

NCT04581629 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

13

Enrollment

INDUSTRY

Sponsor class

Conditions

Autosomal Dominant Hypocalcemia (ADH)
Autosomal Dominant Hypocalcemia Type 1 (ADH1)

Interventions

DRUG: Encaleret

Sponsor

Calcilytix Therapeutics, Inc., a BridgeBio company